US 7153866
Use of tempol for the treatment of Li-Fraumeni syndrome and ataxia telangiectasia
granted A61KA61K31/42A61K31/44
Quick answer
US patent 7153866 (Use of tempol for the treatment of Li-Fraumeni syndrome and ataxia telangiectasia) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Dec 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America, as represented by the Department of Health and Human Services
- Grant date
- Tue Dec 26 2006 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 4
- CPC classes
- A61K, A61K31/42, A61K31/44, A61K31/445